Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Carcinoembryonic Antigen—Still More to Learn From the Real World

Carcinoembryonic Antigen—Still More to Learn From the Real World Preoperative vs Postoperative CEA and Colon Cancer Outcome Original Investigation Research 27. Primrose JN, Perera R, Gray A, et al; FACS Trial survival after complete mesocolic excision with a history of resected colorectal cancer. J Natl Investigators. Effect of 3 to 5 years of scheduled compared with conventional colon cancer surgery: Compr Canc Netw. 2014;12(6):907-913. CEA and CT follow-up to detect recurrence of a retrospective, population-based study. Lancet colorectal cancer. JAMA. 2014;311(3):263-270. Oncol. 2015;16(2):161-168. 28. Bertelsen CA, Neuenschwander AU, Jansen JE, 29. Litvak A, Cercek A, Segal N, et al. False-positive et al; Danish Colorectal Cancer Group. Disease-free elevations of carcinoembryonic antigen in patients Invited Commentary Carcinoembryonic Antigen—Still More to Learn From the Real World Rebecca Anne Miksad, MD, MPH; Neal J. Meropol, MD Carcinoembryonic antigen (CEA) is a group of oncofetal gly- experienced earlier recurrence than patients who had nor- coprotein antigens involved in cell adhesion that was first de- mal baseline or postoperative CEA level. scribed in 1965. Measurement of CEA has long been recom- This study highlights the potential of real-world evidence mended as a blood-based prognostic indicator in colorectal to contribute insights that might ultimately lead to changes cancer and as a surveillance in clinical http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Carcinoembryonic Antigen—Still More to Learn From the Real World

JAMA Oncology , Volume 4 (3) – Mar 21, 2018

Loading next page...
 
/lp/american-medical-association/carcinoembryonic-antigen-still-more-to-learn-from-the-real-world-EKD0hrUUVE

References (5)

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2017.4408
Publisher site
See Article on Publisher Site

Abstract

Preoperative vs Postoperative CEA and Colon Cancer Outcome Original Investigation Research 27. Primrose JN, Perera R, Gray A, et al; FACS Trial survival after complete mesocolic excision with a history of resected colorectal cancer. J Natl Investigators. Effect of 3 to 5 years of scheduled compared with conventional colon cancer surgery: Compr Canc Netw. 2014;12(6):907-913. CEA and CT follow-up to detect recurrence of a retrospective, population-based study. Lancet colorectal cancer. JAMA. 2014;311(3):263-270. Oncol. 2015;16(2):161-168. 28. Bertelsen CA, Neuenschwander AU, Jansen JE, 29. Litvak A, Cercek A, Segal N, et al. False-positive et al; Danish Colorectal Cancer Group. Disease-free elevations of carcinoembryonic antigen in patients Invited Commentary Carcinoembryonic Antigen—Still More to Learn From the Real World Rebecca Anne Miksad, MD, MPH; Neal J. Meropol, MD Carcinoembryonic antigen (CEA) is a group of oncofetal gly- experienced earlier recurrence than patients who had nor- coprotein antigens involved in cell adhesion that was first de- mal baseline or postoperative CEA level. scribed in 1965. Measurement of CEA has long been recom- This study highlights the potential of real-world evidence mended as a blood-based prognostic indicator in colorectal to contribute insights that might ultimately lead to changes cancer and as a surveillance in clinical

Journal

JAMA OncologyAmerican Medical Association

Published: Mar 21, 2018

There are no references for this article.